Michael Tortorici, OD
Optometrist · Elmwood Park, NJNPI 1578643961
Payments from drug & device makers
Across 278 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$540
- Harrow Eye, LLC$411
- Notal Vision, Inc.$373
- Dompe US, Inc.$298
- Alcon$283
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$3737%
- Food & beverage$4,63092%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,066 |
| Sun Pharmaceutical Industries Inc. | 35 | $540 |
| Harrow Eye, LLC | 23 | $411 |
| Notal Vision, Inc. | 1 | $373 |
| Dompe US, Inc. | 13 | $298 |
| Alcon | 15 | $283 |
| Bausch & Lomb Americas Inc. | 22 | $282 |
| Novartis | 19 | $260 |
| Oyster Point Pharma, Inc. | 15 | $237 |
| Tarsus Pharmaceuticals, Inc. | 9 | $203 |
| Biotissue Holdings Inc. | 8 | $168 |
| Mallinckrodt Hospital Products Inc. | 10 | $165 |
| Eyevance Pharmaceuticals LLC | 7 | $120 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $112 |
| LKC Technologies, Inc. | 1 | $77 |
| Shire North American Group Inc | 5 | $69 |
| Aerie Pharmaceuticals, Inc. | 2 | $56 |
| Amgen | 3 | $49 |
| Ocular Therapeutix, Inc. | 3 | $48 |
| Sanofi | 1 | $41 |
| Rayner Intraocular Lenses Limited | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $32 |
| Coopervision Inc. | 1 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Alimera Sciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,021 in reported general payments places this provider in the 90th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 397 | $471,208 |
| XiidraLifitegrast | 185 | $213,715 |
| Cyclosporine | 71 | $50,548 |
| Prednisolone Acetate | 510 | $23,333 |
| Fluorometholone | 189 | $17,102 |
| LumiganBimatoprost | 29 | $15,016 |
| CequaCyclosporine | 15 | $14,648 |
| VyzultaLatanoprostene Bunod | 27 | $13,028 |
| Restasis MultidoseCyclosporine | 14 | $11,143 |
| ZerviateCetirizine Hcl | 15 | $8,635 |
| Loteprednol Etabonate | 34 | $6,645 |
| RhopressaNetarsudil Mesylate | 13 | $5,846 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $5,293 |
| FlarexFluorometholone Acetate | 24 | $5,096 |
| Ketorolac Tromethamine | 148 | $4,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $1,066 | $502,012457 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $282 | $226,743212 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $540 | $14,64815 claims |
| Eyevance Pharmaceuticals LLCZerviate, Flarex | $120 | $13,73139 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $26 | $6,64534 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $56 | $5,84613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Elmwood Park
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Kristen FryTeaneck$66K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Debbie EdegranCloster$53K
- Victoria DzurinkoDeptford$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.